On November 16, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the third quarter ended September 30, 2026. This report is significant as it provides insights into the company's performance and strategic direction within the pharmaceutical preparations sector.
Background
Larimar Therapeutics, Inc. operates in the pharmaceutical preparations industry, classified under SIC 2834. The company trades under the ticker LRMR on the Nasdaq exchange. Recently, it filed an 8-K on November 16, 2026, detailing its financial results for the third quarter.
What the Filing Says
The filing states, "On November 16, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the third quarter ended September 30, 2026." A press release accompanying the report is included as Exhibit 99.1, providing further details on the company's performance.
Impact
This update may affect various stakeholders, including investors, analysts, and competitors in the pharmaceutical industry. Larimar's performance can influence market perceptions and investor decisions regarding the company and its peers.
What's Next
The filing does not say what happens next.
Financial Highlights
The filing does not provide specific financial metrics or detailed results of operations for the third quarter ended September 30, 2026. It mentions that a press release, included as Exhibit 99.1, contains further details on the company's performance.
Company Information
Larimar Therapeutics, Inc. is incorporated in Delaware and operates under the Central Index Key (CIK) 0001374690. The company's fiscal year ends on December 31, and it is classified under the standard industrial classification (SIC) code 2834, which pertains to pharmaceutical preparations.
Contact Information
The company’s principal executive office is located at Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004. For inquiries, stakeholders can reach the company at the business phone number 844-511-9056.
Exhibits
As mentioned in the filing, Exhibit 99.1 contains the press release detailing the financial results and operational highlights. This exhibit is crucial for stakeholders seeking in-depth information regarding the company's performance during the reported period.
Read Next
Vanjia Corp reports Q3 2026 financial results
Sparxx Corp reports Q3 2026 results, shows growth trends
iWallet Corp Reports Q3 Results, Highlights Financial Strategy
HarbourVest Private Equity Secondaries Fund Reports Q2 Results
INVO Fertility Reports 28% Revenue Growth in Q3 Results
KEEMO Fashion Group Reports No Revenue in Latest 10-Q Filing








